德明利公告称，近日控股股东李虎将所持公司775.2万股股份解除质押，占其所持股份比例9.76%，占公 司总股本比例3.42%，质权人为国泰海通证券，质押起始日为2024年12月25日，解除质押日为2025年11 月26日。同时，剩余230万股的解除质押日由原2025年11月25日延期至2026年11月26日。截至公告披露 日，李虎累计质押605万股，占其所持股份比例7.62%，占公司总股本比例2.67%。此前李虎减持计划已 实施完毕，本次解质不会影响公司控制权，质押风险可控。 ...

Core Viewpoint - Lingrui Pharmaceutical announced that its major shareholder, Lingrui Group, will release the pledge of 3.38 million shares on November 20, 2025, which accounts for 2.77% of its holdings and 0.60% of the company's total share capital [1] Summary by Relevant Sections - **Shareholding Structure** - Lingrui Group holds a total of 121,817,898 shares, representing 21.48% of the total share capital of the company [1] - **Pledge Details** - After the release of the pledge, Lingrui Group will have a total of 28,350,000 shares pledged, which is 23.27% of its holdings and 5.00% of the company's total share capital [1] - As of the announcement date, Lingrui Group and its concerted parties have a total of 28,350,000 shares pledged, accounting for 22.18% of their combined holdings and 5.00% of the company's total share capital [1] - **Future Pledge Plans** - Lingrui Group has no plans for subsequent pledges of the released shares [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002384 证券简称：东山精密 公告编号：2025-081 苏州东山精密制造股份有限公司 关于对外投资进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、对外投资概述 苏州东山精密制造股份有限公司（以下简称"公司"）于2025年6月13日召开第六届董事会第二十二次会 议，审议通过了《关于对外投资的议案》，同意公司全资子公司超毅集团（香港）有限公司（以下简 称"香港超毅"）拟收购Source Photonics Holdings (Cayman) Limited（以下简称"索尔思光电"或者"目标公 司"）100%股份（以下简称"本次交易"），以及公司认购其可转债，其中索尔思光电100%股份收购对价 不超过6.29亿美元；索尔思光电ESOP（Employee Stock Option Program，员工期权激励计划，包含在本 次收购方案中）权益收购对价不超过0.58亿美元；为支持索尔思光电经营发展需要以及偿还万通发展认 购的可转债，公司拟认购目标公司不超过10亿元人民币的可转债。上述投资金额 ...

迪瑞医疗公告，公司控股股东华德欣润解除质押4560.02万股，占其所持股份的59%，占公司总股本的 16.72%。解除质押股份起始日为2024年4月15日，解除日期为2025年10月20日，质权人为上海浦东发展 银行股份有限公司深圳分行。华德欣润目前共持有公司7728.84万股，占总股本的28.34%，本次解除质 押后，其股份无质押情形。 ...

Core Viewpoint - Yunda Holdings announced that its controlling shareholder, Shanghai Luojiesi, has released the pledge on 30 million shares, accounting for 1.97% of its holdings and 1.03% of the company's total share capital [1] Summary by Relevant Sections - **Share Pledge Details** - The pledge was initiated on December 27, 2024, and will be released on October 20, 2025 [1] - As of the announcement date, Shanghai Luojiesi and its concerted parties have a total of 214 million shares pledged, which represents 12.81% of their holdings and 7.37% of the company's total share capital [1] - **Risk Assessment** - Currently, there are no risks of forced liquidation or transfer of shares [1]

Core Viewpoint - Jiangsu Guotai announced the release of share pledges by a major shareholder, indicating potential changes in shareholder confidence and liquidity in the company [1] Group 1: Shareholder Actions - Jiangsu Guotai received notification from its major shareholder, Shengtai Investment, regarding the release of 4.33 million shares from pledge [1] - As of the announcement date, Shengtai Investment has a total of 19.29 million shares pledged [1]

Core Viewpoint - The announcement regarding the partial pledge release of shares by the controlling shareholder of Xinlitai has attracted market attention, indicating a positive signal for investor confidence in the company [1]. Summary by Relevant Sections Release of Pledge - Xinlitai Pharmaceutical Co., Ltd. (Hong Kong Xinlitai) has released a total of 1,700,000 shares from pledge, which accounts for 2.68% of its holdings and 1.52% of the company's total share capital [2]. - The released shares include 1,100,000 shares (1.73% of its holdings) and 600,000 shares (0.94% of its holdings), with the pledges initiated on June 13, 2018, and October 11, 2019, respectively, and set to be released by October 14, 2025 [2]. Pledged Shares Situation - As of the announcement date, Xinlitai Pharmaceutical holds 63,527,938 shares, representing 56.99% of the company, with 9,700,000 shares currently under pledge, which is 15.27% of its total holdings and 8.70% of the company's total share capital [3]. - There are no frozen, marked, auctioned, or trust-set shares, nor any non-operational fund occupation or illegal guarantees that could harm the interests of the listed company [3]. Financial Health and Control - Xinlitai Pharmaceutical has a good credit status and repayment capability, indicating that the risks associated with pledged shares are manageable [3]. - The pledge of shares will not lead to any change in the actual control of the company and will not affect its production, operation, or governance [3].

Core Viewpoint - Guangdong Mingzhu Group Co., Ltd. experienced abnormal stock trading fluctuations, with a cumulative closing price increase exceeding 20% over two consecutive trading days, prompting a disclosure according to Shanghai Stock Exchange regulations [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price increased by more than 20% cumulatively on October 10 and October 13, 2025, which is classified as an abnormal trading situation [2][3]. - The static price-to-earnings (P/E) ratio for the black metal mining industry is reported at 27.94, while the company's static P/E ratio is significantly higher at 864.94, indicating potential valuation concerns [2][10]. Group 2: Company Performance and Forecast - The company anticipates a net profit attributable to shareholders of between 215.18 million yuan and 262.99 million yuan for the first three quarters of 2025, representing a year-on-year increase of 858.45% to 1,071.44% [4]. - The expected net profit after deducting non-recurring gains and losses is projected to be between 215.39 million yuan and 263.25 million yuan, with a year-on-year growth of 428.49% to 545.93% [4]. Group 3: Operational Status - The company confirmed that its daily operations and internal production activities are normal, with no significant changes in market conditions or industry policies [5]. - There are no undisclosed major events or transactions that could impact the company's stock price, as verified by the company and its major shareholders [6][9]. Group 4: Shareholder Actions - The major shareholder, Shenzhen Jinxin'an Investment Co., Ltd., holds 109.13 million shares, accounting for 15.72% of the total share capital, and has recently released some pledged shares [21]. - The total number of shares held by the major shareholders and their concerted actions amounts to 236.32 million shares, representing 34.03% of the total share capital, with a significant portion being pledged [22].

Core Viewpoint - Shenzhen Heertai Intelligent Control Co., Ltd. announced the release of part of the shares pledged by its actual controller, Liu Jianwei, indicating a controlled risk in share pledging and no impact on company control [1] Group 1: Share Pledge Details - Liu Jianwei released 9.6 million shares from pledge, accounting for 6.9183% of his holdings and 1.0381% of the company's total share capital [1] - The pledge was held by Shenzhen Small and Medium-sized Guarantee Co., Ltd., with the start date on April 23, 2025, and the release date on September 26, 2025 [1] Group 2: Current Pledge Status - As of the announcement date, Liu Jianwei has a total of 82,918,919 shares pledged, which represents 59.7562% of his holdings [1] - The financing from the pledged shares is not used for the company's production and operation [1] Group 3: Financial Capability - The financing balance corresponding to the pledged shares maturing in the next six months and one year is 50 million yuan and 740 million yuan, respectively [1] - The company has the ability to repay these amounts, indicating that the pledge risk is controllable [1]

Core Viewpoint - The announcement details the early release of share pledges by a major shareholder, Shanghai Hongkang, which may indicate improved financial stability and liquidity for the company [2][3]. Group 1: Share Pledge Release - Shanghai Hongkang has completed the early release of 73,000,000 shares, representing 1.45% of the company's total share capital [2]. - After the release, Shanghai Hongkang holds a total of 1,088,326,782 shares, which is 21.58% of the total share capital, with 466,571,892 shares still pledged, accounting for 42.87% of its holdings and 9.25% of the total share capital [2]. Group 2: Major Shareholder Pledge Situation - As of September 25, 2025, the controlling shareholder, Chuchang Investment, along with its concerted actors, holds 2,290,962,690 shares, which is 45.43% of the total share capital [2]. - Following the early release of shares, the total number of pledged shares held by Chuchang Investment and its concerted actors is 1,076,883,748 shares, reducing the pledged proportion of their holdings to 47.01% and the total share capital to 21.36% [2][3]. Group 3: Financial Stability - The controlling shareholder and its concerted actors have the financial capability to repay the pledged shares, with funding sources including bond issuance, dividends from the listed company, and investment income [3].